{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T06:49:42Z","timestamp":1778050182702,"version":"3.51.4"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["23FC1041"],"award-info":[{"award-number":["23FC1041"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Context<\/jats:title><jats:p>Unilateral primary aldosteronism (uPA) is a surgically curable form of hypertension, frequently associated with resistant hypertension and cerebro-cardiovascular complications. Primary aldosteronism (PA) also negatively affects quality of life (QOL).<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>This study sought to compare the efficacy of mineralocorticoid receptor antagonists (MRAs) and adrenalectomy (ADX) in the treatment of patients with uPA over time within the same patients and to evaluate the efficacy of MRAs in patients with bilateral PA (bPA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Subtype diagnosis of PA was based on adrenal vein sampling results. Clinical parameters, including blood pressure, serum potassium (K), active renin concentration (ARC), aldosterone levels, estimated glomerular filtration rate, and Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) scores, were investigated before and after MRA treatment in all PA patients, as well as after ADX in patients with uPA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The study included 56 patients with bPA and 20 patients with uPA. Changes in parameters with MRA treatment were similar between patients with and without uPA, except for a greater increase in K in patients with uPA. Among patients with uPA, systolic blood pressure and K improved with MRA treatment and showed further improvement following ADX. Diastolic blood pressure and ARC also improved following MRA treatment, with no significant differences observed compared to ADX. SF-36 scores showed no improvement with MRA treatment, but significantly improved after ADX.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The findings showed that ADX generally provides superior clinical, biochemical, and QOL outcomes compared to MRAs in patients with uPA.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2025.1558837","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T04:11:07Z","timestamp":1756440667000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Short-term longitudinal clinical, biochemical, and quality of life outcomes of medical or surgical therapy in unilateral primary aldosteronism"],"prefix":"10.3389","volume":"16","author":[{"given":"Yuichi","family":"Yoshida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Sada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiro","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaaki","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiaki","family":"Yonezu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nao","family":"Imaishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Machiko","family":"Morita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumi","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shotaro","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinori","family":"Ozeki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koro","family":"Gotoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Masaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotaka","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-031337","article-title":"Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents","volume":"89","author":"Mulatero","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.07.059","article-title":"A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients","volume":"48","author":"Rossi","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-4061","article-title":"The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline","volume":"101","author":"Funder","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41440-022-00948-7","article-title":"Prevalence and clinical characteristics of primary aldosteronism in a tertiary-care center in Korea","volume":"45","author":"Yoon","year":"2022","journal-title":"Hypertens Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ando.2016.05.001","article-title":"SFE\/SFHTA\/AFCE primary aldosteronism consensus: Introduction and handbook","volume":"77","author":"Amar","year":"2016","journal-title":"Ann Endocrinol (Paris)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ21-0508","article-title":"Japan Endocrine Society clinical practice guideline for the diagnosis and management of primary aldosteronism 2021","volume":"69","author":"Naruse","year":"2022","journal-title":"Endocr J"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-2116","article-title":"Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn\u2019s Registry","volume":"94","author":"Born-Frontsberg","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.117.10263","article-title":"Prevalence of cardiovascular disease and its risk factors in primary aldosteronism: A multicenter study in Japan","volume":"71","author":"Ohno","year":"2018","journal-title":"Hypertension"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1159\/000093956","article-title":"Psychological aspects of primary aldosteronism","volume":"75","author":"Sonino","year":"2006","journal-title":"Psychother Psychosom"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-1763","article-title":"Improved quality of life, blood pressure, and biochemical status following laparoscopic adrenalectomy for unilateral primary aldosteronism","volume":"95","author":"Sukor","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-0138","article-title":"Quality of life in patients with bilateral primary aldosteronism before and during treatment with spironolactone and\/or amiloride, including a comparison with our previously published results in those with unilateral disease treated surgically","volume":"96","author":"Ahmed","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-2723","article-title":"Psychological assessment of primary aldosteronism: a controlled study","volume":"96","author":"Sonino","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2012.08.025","article-title":"Quality of life in patients with primary aldosteronism: gender differences in untreated and long-term treated patients and associations with treatment and aldosterone","volume":"46","author":"K\u00fcnzel","year":"2012","journal-title":"J Psychiatr Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1210\/jc.2017-01442","article-title":"Quality of life in primary aldosteronism: A comparative effectiveness study of adrenalectomy and medical treatment","volume":"103","author":"Velema","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B15","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12893-018-0432-1","article-title":"Effect of unilateral adrenalectomy on the quality of life of patients with lateralized primary aldosteronism","volume":"18","author":"Citton","year":"2019","journal-title":"BMC Surg"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/iju.14016","article-title":"Changes in quality of life after laparoscopic adrenalectomy for patients with primary aldosteronism: Prospective 2-year longitudinal cohort study in a Japanese tertiary center","volume":"26","author":"Ishidoya","year":"2019","journal-title":"Int J Urol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvab020","article-title":"Quality of life of primary aldosteronism patients by mineralocorticoid receptor antagonists","volume":"5","author":"Yoshida","year":"2021","journal-title":"J Endocr Soc"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41440-023-01412-w","article-title":"Effects of esaxerenone on blood pressure, urinary albumin excretion, serum levels of NT-proBNP, and quality of life in patients with primary aldosteronism","volume":"47","author":"Yoshida","year":"2024","journal-title":"Hypertens Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2018.2003","article-title":"Incidence of atrial fibrillation and mineralocorticoid receptor activity in patients with medically and surgically treated primary aldosteronism","volume":"3","author":"Hundemer","year":"2018","journal-title":"JAMA Cardiol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.118.11568","article-title":"Renal outcomes in medically and surgically treated primary aldosteronism","volume":"72","author":"Hundemer","year":"2018","journal-title":"Hypertension"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000002070","article-title":"Clinical and biochemical outcomes after adrenalectomy and medical treatment in patients with unilateral primary aldosteronism","volume":"37","author":"Katabami","year":"2019","journal-title":"J Hypertens"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41371-019-0241-8","article-title":"Long-term blood pressure outcomes of patients with adrenal venous sampling-proven unilateral primary aldosteronism","volume":"34","author":"Meng","year":"2020","journal-title":"J Hum Hypertens"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14351","article-title":"Outcomes in unilateral primary aldosteronism after surgical or medical therapy","volume":"94","author":"Puar","year":"2021","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1530\/EJE-21-0836","article-title":"Long-term mortality and cardiovascular events in patients with unilateral primary aldosteronism after targeted treatments","volume":"186","author":"Wu","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14630","article-title":"Preoperative mineralocorticoid receptor antagonist reduces postoperative hyperkalaemia in patients with Conn syndrome","volume":"96","author":"Zhang","year":"2022","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa561","article-title":"A comparison of adrenalectomy and eplerenone on vascular function in patients with aldosterone-producing adenoma","volume":"105","author":"Kishimoto","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2021.02.064","article-title":"Differential effects of reduced mineralocorticoid receptor activation by unilateral adrenalectomy vs mineralocorticoid antagonist treatment in patients with primary aldosteronism - Implications for depression and anxiety","volume":"137","author":"Murck","year":"2021","journal-title":"J Psychiatr Res"},{"key":"B28","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3390\/diagnostics11030433","article-title":"Development of a new chemiluminescent enzyme immunoassay using a two-step sandwich method for measuring aldosterone concentrations","volume":"11","author":"Ozeki","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"B29","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41371-020-00465-5","article-title":"Novel chemiluminescent immunoassay to measure plasma aldosterone and plasma active renin concentrations for the diagnosis of primary aldosteronism","volume":"36","author":"Teruyama","year":"2022","journal-title":"J Hum Hypertens"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41440-020-00570-5","article-title":"Efficacy and safety of esaxerenone (CS-3150), a newly available nonsteroidal mineralocorticoid receptor blocker, in hypertensive patients with primary aldosteronism","volume":"44","author":"Satoh","year":"2021","journal-title":"Hypertens Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/s0895-4356(98)00096-1","article-title":"Psychometric and clinical tests of validity of the Japanese SF-36 Health Survey","volume":"51","author":"Fukuhara","year":"1998","journal-title":"J Clin Epidemiol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/s0895-4356(98)00095-x","article-title":"Translation, adaptation, and validation of the SF-36 Health Survey for use in Japan","volume":"51","author":"Fukuhara","year":"1998","journal-title":"J Clin Epidemiol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2009.01.022","article-title":"Estimating a preference-based index from the Japanese SF-36","volume":"62","author":"Brazier","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30367-4","article-title":"Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study","volume":"6","author":"Hundemer","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41440-022-01045-5","article-title":"Importance of dietary salt restriction for patients with primary aldosteronism during treatment with mineralocorticoid receptor antagonists: The potential importance of post-treatment plasma renin levels","volume":"46","author":"Yoshida","year":"2023","journal-title":"Hypertens Res"},{"key":"B36","doi-asserted-by":"publisher","first-page":"6925","DOI":"10.1038\/s41598-021-86290-3","article-title":"Age-stratified comparison of clinical outcomes between medical and surgical treatments in patients with unilateral primary aldosteronism","volume":"11","author":"Nakamaru","year":"2021","journal-title":"Sci Rep"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2015.06.015","article-title":"Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist","volume":"761","author":"Arai","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41440-019-0244-4","article-title":"Systematic review of the clinical outcomes of mineralocorticoid receptor antagonist treatment versus adrenalectomy in patients with primary aldosteronism","volume":"42","author":"Satoh","year":"2019","journal-title":"Hypertens Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.119.14659","article-title":"Initial estimated glomerular filtration rate decline and long-term renal function during intensive antihypertensive therapy: A post hoc analysis of the SPRINT and ACCORD-BP randomized controlled trials","volume":"75","author":"Collard","year":"2020","journal-title":"Hypertension"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.yhbeh.2008.02.004","article-title":"Chronic treatment with the mineralocorticoid hormone aldosterone results in increased anxiety-like behavior","volume":"54","author":"Hlavacova","year":"2008","journal-title":"Horm Behav"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1177\/0269881109106955","article-title":"Eplerenone, a selective mineralocorticoid receptor blocker, exerts anxiolytic effects accompanied by changes in stress hormone release","volume":"24","author":"Hlavacova","year":"2010","journal-title":"J Psychopharmacol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1055\/s-0043-121706","article-title":"Health-related quality of life and mental health in primary aldosteronism: A systematic review","volume":"49","author":"Velema","year":"2017","journal-title":"Horm Metab Res"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/jhh.2009.96","article-title":"Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report","volume":"24","author":"Gaddam","year":"2010","journal-title":"J Hum Hypertens"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/jhh.2017.28","article-title":"Treatment of primary aldosteronism is associated with a reduction in the severity of obstructive sleep apnoea","volume":"31","author":"Wolley","year":"2017","journal-title":"J Hum Hypertens"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1558837\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T04:11:08Z","timestamp":1756440668000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1558837\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":44,"alternative-id":["10.3389\/fendo.2025.1558837"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1558837","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,29]]},"article-number":"1558837"}}